Loading data for TLSA — first visit, this takes a few seconds.

Preisalarm

Tiziana Life Sciences Ltd (TLSA)

NasdaqCM: TLSA · Echtzeitkurs · USD

1.08

-0.04 (-3.57%)

Zum Schluss: Aug 19, 2026, 6:03 PM

-3.57% (1D)

Keine Daten verfügbar

Geld	1.13
Marktkapitalisierung	137.44 Mio
Umsatz (TTM)	n/a
Nettogewinn (TTM)	-18.43 Mio
Beta	0.46
EPS (ttm)	-0.16
KGV (TTM)	n/a
Forward-KGV	-5.41
KBV (TTM)	14.03
KUV (TTM)	n/a
Earnings Date	n/a

Brief	1.11
Volumen	964,789
Ø Vol. (20D)	479,979
Eröffnung	1.12
Vortagesschluss	1.12
Tagesspanne	1.05 - 1.17
52-Wk Range	0.87 - 2.35
Analyst	n/a
Kursziel	n/a
Dividenden	n/a
Ex-Dividenden-Datum	n/a

Über TLSA

Tiziana Life Sciences Ltd, together with its subsidiaries, engages in the research and development of therapies for neurodegenerative and neuroinflammatory diseases in the United Kingdom and internationally. It develops Foralumab TZLS-401, a human anti-CD3 monoclonal antibody, which is Phase II clinical trial for the treatment of non-active secondary progressive multiple sclerosis, Alzheimer's disease, multi system atrophy, and amyotrophic latera...

[Mehr lesen]

Branche Biotechnology

Sektor Healthcare

IPO Datum Nov 20, 2018

Mitarbeiter 10

Börse NasdaqCM

Tickersymbol TLSA

Website https://www.tizianalifesciences.com

Vollständiges Unternehmensprofil

Finanzielle Entwicklung

Im Jahr 2025 betrug der Umsatz von Tiziana Life Sciences Ltd 0, ein Anstieg von undefined% im Vergleich zum Vorjahr (0). Der Gewinn lag bei -18.43 Mio, ein Anstieg von 55.37 %.

Finanzberichte

Gewinnüberraschung

Tiziana Life Sciences Ltd hat die Quartalszahlen am Dec 27, 2022 veröffentlicht:

Umsatz von n/a verfehlt die Erwartungen um $0, mit NaN% Wachstum im Jahresvergleich.

EPS von -0.06 verfehlt die Erwartungen um , mit -Infinity% Rückgang im Jahresvergleich.

Nachrichten

vor 2 Wochen · Proactive

Tiziana Life Sciences reports reductions in brain inflammation in third MSA patient

Tiziana Life Sciences Ltd (NASDAQ:TLSA) has reported imaging results from the third patient with multiple system atrophy (MSA) to complete dosing in its ongoing Phase 2 clinical trial of intranasal fo...

vor 1 Monat · Proactive

Tiziana Life Sciences doses last patient in Phase 2a multiple sclerosis trial

Tiziana Life Sciences Ltd (NASDAQ:TLSA) said the last patient in its Phase 2a clinical trial has received a first dose of intranasal foralumab for the treatment of non-active Secondary Progressive Mul...

vor 2 Monaten · Motley Fool

Innoviva Stock Is Up Just 10% This Past Year. Here's Why a Fund Bought $2.5 Million More

Innoviva develops respiratory pharmaceuticals through strategic partnerships and royalty agreements in the global healthcare market.

vor 2 Monaten · Proactive

Tiziana Life Sciences advances foralumab program with full Phase 2 enrollment and encouraging expanded access data – ICYMI

Tiziana Life Sciences Ltd (NASDAQ:TLSA) has completed enrollment in its Phase 2 clinical trial evaluating foralumab for secondary progressive multiple sclerosis (SPMS), while also reporting expanded a...

vor 2 Monaten · Proactive

Tiziana Life Sciences completes enrollment in Phase 2a multiple sclerosis trial

Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has completed patient enrollment in its Phase 2a clinical trial evaluating intranasal foralumab in patients with non-active secondary progress...

Seite 1 von 2

Tiziana Life Sciences Ltd (TLSA)